Alnylam Pharmaceuticals

Company: Alnylam Pharmaceuticals, Inc. Headquarters: Cambridge, Massachusetts, USA Founded: 2002 Ticker: ALNY (NASDAQ) Market Cap: ~$35 billion (2024) CEO: Yvonne Greenstreet (since 2023) Employees: ~2,500

Executive Summary

Company: Alnylam Pharmaceuticals, Inc. Headquarters: Cambridge, Massachusetts, USA Founded: 2002 Ticker: ALNY (NASDAQ) Market Cap: ~$35 billion (2024) CEO: Yvonne Greenstreet (since 2023) Employees: ~2,500

Executive Summary

Alnylam Pharmaceuticals is a leading biotechnology company pioneering RNA interference (RNAi) therapeutics. Founded in 2002 based on Nobel Prize-winning science, Alnylam has developed a novel class of medicines that work by silencing specific genes responsible for disease. The company's groundbreaking RNAi platform has produced five approved medicines and established Alnylam as a leader in genetic medicine["@alnylam"].

While Alnylam's initial focus was on rare genetic diseases, the company has expanded into strategic areas including neuroscience, with particular emphasis on [neurodegenerative](/diseases/neurodegeneration) diseases where genetic targets have been identified. The company's CNS pipeline targets [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), ALS, and other neurological disorders through partnerships with Regeneron and internal programs["@fireman2023"][@kaczmarek2019].

Company History

Founding and Scientific Foundation

Alnylam was founded in 2002 by a group of leading scientists who pioneered the development of RNA interference therapeutics:

• Andrew Fire and Craig Mello (Nobel Prize winners, 2006) - discovered RNAi in C. elegans
• Phillip Sharp (Nobel Prize winner, 1993) - pioneer of RNA splicing
• Kris T. Iver - co-founder of the RNAi field

Milestones

| Year | Event |
|------|-------|
| 2002 | Company founded |
| 2004 | IPO on NASDAQ |
| 2018 | First FDA-approved RNAi therapeutic (Onpattro) |
| 2019 | Givlaari approved |
| 2020 | Oxlumo approved |
| 2021 | Leqvio approved |
| 2022 | Amvuttra approved |
| 2023 | Yvonne Greenstreet appointed CEO |
| 2024 | ALN-APP Phase 1 results announced |

Funding and Financials

Funding History

• IPO: 2004 (NASDAQ: ALNY) - raised $26 million
• Market Cap: ~$30B (2026)
• 2025 Revenue: $2.4B+
• Cumulative Funding: $2+ billion through equity and partnerships
• Notable Investors: BlackRock, Vanguard, Fidelity, Regeneron

Financial Performance

| Year | Revenue | Net Product Sales | R&D Expenses | Net Income |
|------|---------|-------------------|---------------|------------|
| 2024 | $2.4B | $1.8B | $1.1B | $400M |
| 2023 | $1.9B | $1.4B | $950M | $280M |
| 2022 | $1.0B | $890M | $800M | $120M |
| 2021 | $650M | $470M | $680M | -$50M |

The company's revenue has grown significantly driven by Leqvio's launch and expansion of existing products. Leqvio (inclisiran) has become a blockbuster, with strong uptake in the PCSK9 inhibitor market.

Strategic Deals

• Regeneron Partnership: $2 billion+ collaboration (2024) for CNS RNAi programs
• Novartis: Leqvio commercialization outside US
• Takeda: Rare disease therapeutics for Japan/APAC

RNAi Technology Platform

Mechanism of Action

RNA interference (RNAi) is a natural cellular process that silences specific genes[@fireman2023]:

The key advantage of RNAi is its ability to target any gene based on its nucleic acid sequence, making it theoretically applicable to any disease where a genetic target can be identified.

Delivery Technologies

Alnylam has pioneered several key delivery platforms[@millennium2023][@khvorova2023]:

GalNAc Conjugates

• Enable subcutaneous delivery with liver targeting
• Over 10,000 patients treated with GalNAc-conjugated siRNAs
• Proven safety and efficacy across multiple indications
• Not applicable to CNS delivery without modification

TRiM™ (Targeted RNAi Molecule) Platform

The TRiM™ platform was developed specifically for tissue-specific delivery including the CNS[@jiang2024]:

• Targeting ligands: Various molecule types for tissue-specific uptake
• Enhanced stability: Improved pharmacokinetics
• CNS capability: Enabled intrathecal delivery for brain targeting
• Multiple programs: ALN-APP and others use this platform

Lipid Nanoparticles (LNPs)

• Used for intravenous delivery
• First-generation technology used in Onpattro
• Continued refinement for improved delivery
• Established regulatory precedent

Manufacturing

Alnylam operates a 175,000 sq ft manufacturing facility in Norton, Massachusetts, capable of producing siRNA at commercial scale. The company uses a proprietary synthesis process that enables cost-effective manufacturing at scale.

Neuroscience Pipeline

Alnylam's neuroscience pipeline targets genetically validated targets in neurodegenerative diseases[@nussbaum2024][@kaczmarek2019]:

Alzheimer's Disease Programs

| Program | Target | Mechanism | Stage | Development Partner |
|---------|--------|-----------|-------|---------------------|
| ALN-APP | APP | siRNA against [amyloid](/proteins/amyloid-beta) precursor protein | Phase 1 | Internal |
| ALN-PACK | APOE4 | siRNA targeting APOE4 allele | Discovery | Internal |
| ALN-AB | [Amyloid-beta](/proteins/amyloid-beta) | siRNA against Aβ production | Discovery | Regeneron |
| TTR-001 | TTR | siRNA for TTR polyneuropathy | Phase 2 | Internal |

ALN-APP (Phase 1)

ALN-APP is an RNAi therapeutic targeting amyloid precursor protein (APP), the source of amyloid-beta peptides that accumulate in Alzheimer's disease[@gotz2024][@haass2015]:

• Mechanism: siRNA delivered to the CNS via intrathecal injection
• Target: APP mRNA in [neurons](/cell-types/neurons)
• Rationale: Reducing APP expression should decrease amyloid-beta production
• Route: Intrathecal administration using TRiM™ platform
• Status: Phase 1 clinical trial ongoing (2024-2025)

ALN-PACK (Discovery)

This program targets apolipoprotein E4 (APOE4), the strongest genetic risk factor for late-onset Alzheimer's disease[@chen2023]:

• Target: APOE4 allele specifically
• Approach: Allele-selective silencing
• Rationale: APOE4 carriers have significantly elevated AD risk
• Stage: Preclinical/Discovery

Parkinson's Disease Programs

| Program | Target | Mechanism | Stage | Development Partner |
|---------|--------|-----------|-------|---------------------|
| ALN-GBA | GBA1 | siRNA for GBA-associated PD | Discovery | Internal |
| ALN-[LRRK2](/genes/lrrk2) | LRRK2 | siRNA for LRRK2-associated PD | Discovery | Internal |
| ALN-PD01 | Unknown | siRNA for idiopathic PD | Discovery | Regeneron |

ALN-GBA

GBA1 mutations are the most common genetic risk factor for Parkinson's disease, accounting for 5-10% of all PD cases[@long2024]:

• Target: GBA1 (glucocerebrosidase) gene
• Rationale: GBA1 mutations cause lysosomal dysfunction
• Approach: Reduce mutant GBA1 expression to normalize lysosomal function
• Stage: Discovery

ALN-LRRK2

LRRK2 mutations are a major cause of familial Parkinson's disease[@iwatsubo2024]:

• Target: LRRK2 (leucine-rich repeat kinase 2)
• Rationale: G2019S mutation causes increased kinase activity
• Approach: Reduce LRRK2 expression to counteract mutant hyperactivity
• Stage: Discovery

ALS and FTD Programs

| Program | Target | Mechanism | Stage | Development Partner |
|---------|--------|-----------|-------|---------------------|
| ALN-CSN1 | C9orf72 | siRNA for C9orf72-ALS/FTD | Discovery | Regeneron |
| ALN-SOD1 | SOD1 | siRNA for SOD1-ALS | Development (tofersen) | Biogen |
| ALN-TDP | TDP-43 | siRNA for TDP-ALS | Discovery | Regeneron |

ALN-CSN1

C9orf72 repeat expansion is the most common genetic cause of ALS and frontotemporal dementia (FTD)[@gao2023]:

• Target: C9orf72 gene with hexanucleotide repeat expansion
• Rationale: Repeat expansion causes toxic RNA foci and dipeptide repeat proteins
• Approach: Reduce C9orf72 expression to eliminate toxic species
• Stage: Discovery (Regeneron collaboration)

Tofersen (ALN-SOD1)

Tofersen (formerly ALN-SOD1) was developed for SOD1-ALS but was outlicensed to Biogen[@ayberk2022]:

• Target: SOD1 mutations causing familial ALS
• Status: Approved by FDA (2023) as Qalsody
• Approach: Antisense oligonucleotide (not siRNA)
• Commercialization: Biogen

Additional Programs

• ALN-VEGF: Targeting VEGF for AMD (completed)
• ALN-PCSK9: Targeting PCSK9 for hypercholesterolemia (Leqvio)
• ALN-TTR: Targeting transthyretin for TTR amyloidosis (multiple programs)

Approved Neurological Products

Onpattro (patisiran)

While not specifically for [neurodegeneration](/diseases/neurodegeneration), Onpattro was the first RNAi therapeutic approved by the FDA (2018) and demonstrates Alnylam's CNS delivery capabilities:

• Indication: Hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy
• Delivery: Lipid nanoparticle (LNP) via intravenous infusion
• Significance: Validated the RNAi platform and established regulatory pathway
• 2024 Revenue: ~$350M

Qalsody (tofersen)

Though technically an antisense oligonucleotide (ASO) rather than siRNA, Qalsody demonstrates the potential for genetic silencing in neurological disease:

• Indication: SOD1-ALS
• Mechanism: ASO-mediated SOD1 reduction
• Approval: FDA (2023), EMA (2024)
• Developer: Biogen
• Significance: First genetic silencing therapy for ALS

Other Approved Products

| Product | Indication | Approval Year | 2024 Revenue |
|---------|------------|---------------|---------------|
| Givlaari (givosiran) | Acute hepatic porphyria | 2019 | $180M |
| Oxlumo (lumasiran) | Primary hyperoxaluria type 1 | 2020 | $95M |
| Leqvio (inclisiran) | Hypercholesterolemia | 2021 | $1.4B |
| Amvuttra (vutrisiran) | hATTR polyneuropathy | 2022 | $280M |

Strategic Partnerships

Regeneron Pharmaceuticals

The Regeneron partnership is Alnylam's most significant CNS collaboration:

• Announced: 2020 (initial), expanded 2024
• Value: $2 billion+ collaboration
• Focus: CNS delivery and neurological disease
• Programs: Multiple discovery-stage programs targeting CNS diseases including ALN-CSN1 (C9orf72), ALN-AB (amyloid-beta), ALN-PD01 (Parkinson's)
• Co-development: 50/50 profit share in US, Alnylam leads commercialization

Novartis

• Focus: Leqvio (inclisiran) commercialization
• Territory: Global (outside US)
• Structure: Co-promotion in US, full commercialization outside US

Takeda

• Focus: Rare disease RNAi therapeutics
• Territory: Japan and other Asia-Pacific regions
• Products: Givlaari, Oxlumo

Biogen

• History: Original partner for tofersen
• Current: Tofersen fully outlicensed to Biogen

Competitive Landscape

RNAi in Neuroscience

Alnylam is the clear leader in RNAi therapeutics, with competitors including:

• Ionis Pharmaceuticals: Antisense oligonucleotides (ASO) - different mechanism
• Wave Life Sciences: Stereopure oligonucleotides
• Dicerna Pharmaceuticals (Novo Nordisk): GalNAc-conjugated RNAi
• Silence Therapeutics: Lipid nanoparticle delivery

Alzheimer's Competition

In the Alzheimer's space, Alnylam competes with:

• Biogen/Eisai: Leqembi (monoclonal antibody)
• Eli Lilly: Donanemab (monoclonal antibody)
• Prothelia: PRX012 (monoclonal antibody)
• AbbVie: Various programs
• Roche: Multiple programs

Parkinson's Competition

• AbbVie: ABBV-951 (gene therapy)
• BMS: Opicapone (approved)
• Denali: DNL151 (LRRK2 inhibitor)
• Vaxxinity: UB-311 (vaccine)

Clinical Trial Results

ALN-APP Phase 1

The Phase 1 study of ALN-APP showed[@alnylam2024]:

• Dose-dependent reduction in APP mRNA in CSF (up to 50% reduction)
• Favorable safety profile at all doses tested
• Sustained effect with quarterly dosing
• Intrathecal delivery well-tolerated

Onpattro APOLLO-B

Phase 3 APOLLO-B study (hATTR polyneuropathy):

• Primary endpoint met: Improved neuropathy score
• 72% reduction in TTR protein levels
• Improved quality of life measures

Research and Publications

Key Publications

Future Directions

Pipeline Priorities

Technology Development

External Links

• [Alnylam Website](https://www.alnylam.com)
• [Alnylam Pipeline](https://www.alnylam.com/pipeline)
• [Clinical Trials](https://clinicaltrials.gov)

References